Eli Lilly and Company (NYSE:LLY) Shares Unloaded Rep. Lizzie Fletcher

Key Points

• Rep. Lizzie Fletcher disclosed selling between $1,001 and $15,000 of Eli Lilly (LLY) stock on April 8 in her FILER BROKERAGE ACCOUNT, and made similar-sized sales of several other major tech and financial holdings the same day.
• Eli Lilly reported a blowout Q1 — $8.55 non‑GAAP EPS on $19.8B revenue — and raised FY2026 guidance to $35.50–37.00 EPS and $82–85B revenue, a key driver of a roughly 3.3% stock lift.
• Analysts remain largely bullish with a consensus "Moderate Buy" and an average target near $1,219, though commentary warns of valuation stretch and competitive/pricing risks from rivals and payors.

Representative Lizzie Fletcher (Democratic-Texas) recently sold shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on May 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on April 8th. The trade occurred in the Representative's "FILER BROKERAGE ACCOUNT (CB)" account.

Representative Lizzie Fletcher also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 4/8/2026.
• Sold $1,001 - $15,000 in shares of KLA NASDAQ: KLAC on 4/8/2026.
• Sold $1,001 - $15,000 in shares of Eaton NYSE: ETN on 4/8/2026.
• Sold $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/8/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 4/8/2026.
• Sold $1,001 - $15,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 4/8/2026.
• Sold $1,001 - $15,000 in shares of Quanta Services NYSE: PWR on 4/8/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 4/8/2026.
• Sold $1,001 - $15,000 in shares of Ameriprise Financial NYSE: AMP on 4/8/2026.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/8/2026.

Eli Lilly and Company Trading Up 3.3%

Eli Lilly and Company stock opened at $965.19 on Friday. The firm has a 50-day moving average of $947.05 and a 200-day moving average of $984.98. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market cap of $911.93 billion, a price-to-earnings ratio of 42.06, a P/E/G ratio of 1.10 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 115.33%. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the business posted $3.34 EPS. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LLY shares. Leerink Partners reduced their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating for the company in a research note on Monday, April 27th. Royal Bank Of Canada started coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They set an "outperform" rating and a $1,250.00 price objective for the company. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday. Daiwa Securities Group upped their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a "buy" rating in a report on Wednesday, February 18th. Finally, TD Cowen upped their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,218.93.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of LLY. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. raised its holdings in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. Flow Traders U.S. LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $356,000. Finally, Nebula Research & Development LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $749,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

About Representative Fletcher

Lizzie Pannill Fletcher (Democratic Party) is a member of the U.S. House, representing Texas' 7th Congressional District. She assumed office on January 3, 2019. Her current term ends on January 3, 2027. Fletcher (Democratic Party) ran for re-election to the U.S. House to represent Texas' 7th Congressional District. She won in the general election on November 5, 2024. Lizzie Pannill Fletcher was born and lives in Houston, Texas. She graduated from St. John's School. She earned a bachelor's degree in history from Kenyon College and a J.D. from William & Mary Law School. Fletcher’s career experience includes working as a lawyer. She co-founded Planned Parenthood Young Leaders in 2000. Fletcher serves as a board member of Writers in the Schools and Open Dance Project.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.